ScinoPharm Taiwan, Ltd. (TPE:1789)

Market Cap	16.13B +7.1%
Revenue (ttm)	3.14B -2.3%
Net Income	107.46M -56.2%
EPS	0.13 -57.1%
Shares Out	790.74M
PE Ratio	153.44
Forward PE	n/a
Dividend	0.29 (1.43%)
Ex-Dividend Date	Jul 2, 2026

Volume	803,301
Open	20.50
Previous Close	20.40
Day's Range	20.05 - 20.55
52-Week Range	16.25 - 29.10
Beta	0.42
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 5, 2026

About ScinoPharm Taiwan

ScinoPharm Taiwan, Ltd., a pharmaceutical company, provides active pharmaceutical ingredient (API) development and manufacturing and injectable solutions in Taiwan, rest of Asia, Europe, and the Americas. It offers small molecules, peptide drugs, and steroids; drug products for anticancer, thromboembolic disorders, and osteoporosis; and contract analytical testing, sterile injectables contract manufacturing, and small molecules and peptide contract development and manufacturing organization services. The company was incorporated in 1997 and is ...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1997
• Employees: 540
• Stock Exchange: Taiwan Stock Exchange
• Ticker Symbol: 1789

Financial Performance

In 2025, ScinoPharm Taiwan's revenue was 3.16 billion, a decrease of -7.13% compared to the previous year's 3.41 billion. Earnings were 136.95 million, a decrease of -59.64%.